2022 ASCO Annual Meeting coverage

Harold Burstein takes us through the breast cancer studies that caught his attention at the 2022 ASCO Annual Meeting, including the DESTINY-Breast04 and LUMINA trials.

15-06-2022 | ASCO 2022 | Conference coverage | Video

Reflections on the DESTINY-Breast04 trial

Patricia LoRusso provides an independent comment on the DESTINY-Breast04 trial showing the benefit of trastuzumab deruxtecan for people with HER2-low metastatic breast cancer, and discusses the challenges involved.

Genitourinary cancers at ASCO 2022

14-06-2022 | ASCO 2022 | Conference coverage | News

JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

09-06-2022 | ASCO 2022 | Conference coverage | News

Biomarker may predict neoadjuvant treatment response in bladder cancer

07-06-2022 | ASCO 2022 | Conference coverage | News

OS data reported from TheraP trial of LuPSMA in mCRPC

07-06-2022 | ASCO 2022 | Conference coverage | News

ENZAMET update confirms benefits of add-on enzalutamide

06-06-2022 | ASCO 2022 | Conference coverage | News

Acetaminophen may blunt ICI response in people with cancer

05-06-2022 | ASCO 2022 | Conference coverage | News

More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC

05-06-2022 | ASCO 2022 | Conference coverage | News

Enfortumab vedotin offers sustained benefit over 2 years in advanced UC

04-06-2022 | ASCO 2022 | Conference coverage | News

Adjuvant everolimus may benefit RCC patients at high risk for recurrence

04-06-2022 | ASCO 2022 | Conference coverage | News

No benefit of maintenance cabozantinib in unselected patients with mUC

13-06-2022 | ASCO 2022 | Conference coverage | Video

EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

06-06-2022 | ASCO 2022 | Conference coverage | Video

ATLANTIS rules out cabozantinib as a maintenance option for mUC

Robert Jones explains why the ATLANTIS trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of VEGFR-targeted therapies in this tumor type.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

03-06-2022 | ASCO 2022 | Conference coverage | Video

COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

Sumanta Pal outlines results from three cohorts of the COSMIC-021 trial pointing to the potential of combining cabozantinib with atezolizumab in treatment-naïve and pretreated advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Lung & thoracic cancers at ASCO 2022

08-06-2022 | ASCO 2022 | Conference coverage | News

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Medicine Matters Oncology

2022 ASCO Annual Meeting coverage

Breast cancer at ASCO 2022

ctDNA identifies patients before late HR-positive breast cancer recurrence

Omitting radiotherapy may be feasible for luminal A, low-risk breast cancer

Overall survival benefits shown for capivasertib in AI-resistant breast cancer

DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer

Ribociclib plus endocrine therapy switch benefits CDK4/6 progressors

Survival benefits unclear for add-on palbociclib in advanced breast cancer

TROPiCS-02 supports sacituzumab govitecan for HR+, HER2– advanced breast cancer

Breast cancer highlights from the 2022 ASCO Annual Meeting

Reflections on the DESTINY-Breast04 trial

Genitourinary cancers at ASCO 2022

JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

Biomarker may predict neoadjuvant treatment response in bladder cancer

OS data reported from TheraP trial of LuPSMA in mCRPC

ENZAMET update confirms benefits of add-on enzalutamide

Acetaminophen may blunt ICI response in people with cancer

More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC

Enfortumab vedotin offers sustained benefit over 2 years in advanced UC

Adjuvant everolimus may benefit RCC patients at high risk for recurrence

No benefit of maintenance cabozantinib in unselected patients with mUC

EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC

ATLANTIS rules out cabozantinib as a maintenance option for mUC

COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

Lung & thoracic cancers at ASCO 2022

Lung-MAP: Post-immunotherapy ramucirumab plus pembrolizumab improves NSCLC survival

NADIM II validates use of neoadjuvant nivolumab–chemo use in stage IIIA–B NSCLC

Acetaminophen may blunt ICI response in people with cancer

SKYSCRAPER-02: Add-on tiragolumab ineffective in extensive-stage SCLC

Amivantamab updates confirm NSCLC efficacy for certain patients

No survival benefit by adding chemotherapy to immunotherapy in PD-L1-high NSCLC

COSMIC-021 points to cabozantinib–atezolizumab potential for ICI-treated metastatic NSCLC

Stay informed with Medicine Matters